Table 3 Risk factors for nivolumab-induced pneumonitis in patients with solid tumors by univariate and multivariate logistic regression analysis

Age, years

≥65 vs. < 65

3.05

(1.08–10.90)

0.034

(0.44–6.11)

Sex

Male vs. female

10.13

(2.03–183.77)

0.0018

(1.01–104.40)

Smoking status

Current/ex-smoker vs. Never-smoker

1.52

(0.53–5.50)

0.45

Performance status

≥2 vs. 0 or 1

0.75

(0.17–2.38)

0.64

Tumor types

NSCLC vs. HNC/GC

1.79

(0.73–4.70)

0.21

Pre-existing ILD

Yes vs. No

9.42

(3.67–25.80)

< 0.0001

(2.07–18.54)

NLR^a

≥2.5 vs. < 2.5

0.87

(0.35–2.22)

0.76

≥5.0 vs. < 5.0

0.68

(0.21–1.82)

0.45

LDH (IU/l)

≥240 vs. < 240

1.52

(0.59–3.74)

0.37

CRP (mg/dl)

≥1 vs. < 1

0.71

(0.27–1.75)

0.46